NCT05252078View on ClinicalTrials.gov

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsEsophageal DiseasesGastrointestinal NeoplasmsGastrointestinal DiseasesDigestive System NeoplasmsDigestive System DiseasesNeoplasms by SiteNeoplasms by Histologic TypeNeoplasms, Squamous CellCarcinoma, Squamous Cell
Interventions
DRUG

Anlotinib hydrochloride

Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.

DRUG

TQB2450

TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.

Trial Locations (1)

Unknown

RECRUITING

Jiangxi Cancer Hospital, Nanchang

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Jiangxi Provincial Cancer Hospital

OTHER